Hypothalamic corticotrophin-releasing factor and norepinephrine mediate sympathetic and cardiovascular responses to acute intracarotid injection of tumour necrosis factor-alpha in the rat.
Systemic administration of tumour necrosis factor (TNF)-alpha induces the release of norepinephrine in the paraventricular nucleus (PVN) of hypothalamus and an increase in expression of corticotrophin-releasing factor (CRF) and CRF type 1 receptors. We explored the hypothesis that CRF and norepinephrine in PVN mediate the cardiovascular and sympathetic responses to acute systemic administration of TNF-alpha. In anaesthetised rats, the increases in arterial pressure and heart rate induced by intracarotid artery injection of TNF-alpha were attenuated by intracerebroventricular (ICV) injection of either the alpha 1-adrenergic antagonist prazosin or the CRF antagonist alpha-helical CRF. Prazosin blocked the TNF-alpha-induced increase in renal sympathetic nerve activity (RSNA), whereas alpha-helical CRF substantially reduced the RSNA response. Conversely, CRF and the alpha 1-adrenergic agonist phenylephrine, administered ICV, both elicited increases in PVN neuronal activity, RSNA, arterial pressure and heart rate. Microinjection of CRF and phenylephrine directly into PVN evoked smaller responses. These results are consistent with the hypothesis that norepinephrine and CRF in the PVN mediate the cardiovascular and sympathetic responses to acute systemic administration of TNF-alpha.
Zhang
Z-H
ZH
Department of Internal Medicine, University of Iowa, Iowa, IA 52242, USA.
Felder
R B
RB
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology; D002319:Cardiovascular System / Q000187:drug effects* / Q000378:metabolism; D002339:Carotid Arteries / Q000187:drug effects; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D006339:Heart Rate / Q000187:drug effects; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D007269:Injections, Intra-Arterial; D007276:Injections, Intraventricular; D008297:Male; D009474:Neurons / Q000187:drug effects; D009638:Norepinephrine / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D010656:Phenylephrine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013564:Sympathetic Nervous System / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000494:pharmacology*
D000959:Antihypertensive Agents; D002316:Cardiotonic Agents; D014409:Tumor Necrosis Factor-alpha; D010656:Phenylephrine; D003346:Corticotropin-Releasing Hormone; D009638:Norepinephrine; D011224:Prazosin
Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10
15173056
Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H423-33
12063317
Eur Heart J. 2005 Feb;26(4):357-62
15618038
J Neuroimmunol. 1996 Nov;70(2):163-79
8898725
Fed Proc. 1985 Jan;44(1 Pt 2):243-8
2981744
Endocrinology. 1994 Nov;135(5):2177-82
7956940
J Physiol. 1979 Mar;288:159-69
469713
Proc Soc Exp Biol Med. 2000 Jan;223(1):22-38
10632958
J Comp Neurol. 2000 Dec 4;428(1):5-20
11058221
Psychoneuroendocrinology. 1996 Jan;21(1):83-93
8778906
J Neurosci. 2002 Jul 1;22(13):5606-18
12097512
Circulation. 2002 Mar 5;105(9):1135-43
11877368
Neurochem Int. 2008 May;52(6):1220-5
18280616
Clin Chim Acta. 1999 Feb;280(1-2):127-34
10090530
Am J Cardiol. 1997 Dec 4;80(11A):26L-40L
9412540
J Appl Physiol (1985). 2006 Apr;100(4):1392-9
16322371
Brain Res Mol Brain Res. 1996 May;38(1):166-70
8737681
Minerva Endocrinol. 2004 Jun;29(2):47-54
15257255
J Neuroendocrinol. 2005 Aug;17(8):498-508
16011486
Ciba Found Symp. 1993;172:5-21; discussion 21-9
8491094
Brain Behav Immun. 2008 May;22(4):573-89
18191534
Hum Psychopharmacol. 2004 Aug;19(6):397-403
15303243
Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H923-4
16467462
Ann N Y Acad Sci. 2000;917:38-67
11268364
Neuroendocrinology. 1987 Aug;46(2):143-6
2819759
Circulation. 1998 Sep 29;98(13):1329-34
9751683
J Comp Neurol. 1993 Jul 8;333(2):151-67
7688383
J Neurochem. 2000 May;74(5):2134-45
10800959
Eur Heart J. 2001 Jul;22(13):1136-43
11428854
Circulation. 2001 Apr 24;103(16):2055-9
11319194
Panminerva Med. 2005 Jun;47(2):75-80
16210992
Circ Res. 2002 Nov 29;91(11):988-98
12456484
Pharmacol Rev. 2000 Dec;52(4):595-638
11121511
Endocrinology. 1996 Nov;137(11):4619-29
8895325
Ann N Y Acad Sci. 2000;917:608-17
11268389
Front Biosci. 2003 Sep 01;8:s1321-9
12957837
Am J Physiol Heart Circ Physiol. 2002 Mar;282(3):H890-5
11834483
Am J Physiol Regul Integr Comp Physiol. 2002 Aug;283(2):R281-3
12121837
Curr Opin Clin Nutr Metab Care. 2002 Sep;5(5):551-9
12172480
Physiol Rev. 1994 Apr;74(2):323-64
8171117
Brain Res. 1987 Dec 29;437(2):253-63
3325130
Acta Physiol Scand. 2003 Mar;177(3):209-18
12608991
J Neurosci. 2002 Feb 1;22(3):959-69
11826124
J Neurosci. 1997 Sep 15;17(18):7166-79
9278551
J Neuroendocrinol. 1994 Dec;6(6):689-96
7894472
J Neurosci. 1995 Apr;15(4):2680-95
7722622
Ciba Found Symp. 1993;172:243-53; discussion 253-7
8491089
Cytokine. 2004 Oct 21;28(2):87-91
15381186
Am J Physiol Regul Integr Comp Physiol. 2003 Apr;284(4):R916-27
12626358
Prog Brain Res. 1982;57:267-77
6296919